Currently, PD-L1 protein expression is the only approved biomarker for ICI in NSCLC in Europe, while tumour mutational burden (TMB) and microsatellite instability (MSI) are additionally approved by the FDA in an entity-agnostic manner. The gene discussed is CD274; the disease is non-small cell lung carcinoma.